98 related articles for article (PubMed ID: 33683117)
1. Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.
Nissink JWM; Bazzaz S; Blackett C; Clark MA; Collingwood O; Disch JS; Gikunju D; Goldberg K; Guilinger JP; Hardaker E; Hennessy EJ; Jetson R; Keefe AD; McCoull W; McMurray L; Olszewski A; Overman R; Pflug A; Preston M; Rawlins PB; Rivers E; Schimpl M; Smith P; Truman C; Underwood E; Warwicker J; Winter-Holt J; Woodcock S; Zhang Y
J Med Chem; 2021 Mar; 64(6):3165-3184. PubMed ID: 33683117
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
Baladi T; Aziz J; Dufour F; Abet V; Stoven V; Radvanyi F; Poyer F; Wu TD; Guerquin-Kern JL; Bernard-Pierrot I; Garrido SM; Piguel S
Bioorg Med Chem; 2018 Nov; 26(20):5510-5530. PubMed ID: 30309671
[TBL] [Abstract][Full Text] [Related]
4. UNC5293, a potent, orally available and highly MERTK-selective inhibitor.
Zheng H; Zhao J; Li B; Zhang W; Stashko MA; Minson KA; Huey MG; Zhou Y; Earp HS; Kireev D; Graham DK; DeRyckere D; Frye SV; Wang X
Eur J Med Chem; 2021 Aug; 220():113534. PubMed ID: 34038857
[TBL] [Abstract][Full Text] [Related]
5. Promiscuity and selectivity of small-molecule inhibitors across TAM receptor tyrosine kinases in pediatric leukemia.
Liu MH; Chen SB; Yu J; Liu CJ; Zhang XJ
J Mol Graph Model; 2017 Aug; 75():125-131. PubMed ID: 28551502
[TBL] [Abstract][Full Text] [Related]
6. Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.
Zhao J; Zhang D; Zhang W; Stashko MA; DeRyckere D; Vasileiadi E; Parker RE; Hunter D; Liu Q; Zhang Y; Norris-Drouin J; Li B; Drewry DH; Kireev D; Graham DK; Earp HS; Frye SV; Wang X
J Med Chem; 2018 Nov; 61(22):10242-10254. PubMed ID: 30347155
[TBL] [Abstract][Full Text] [Related]
7. A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding.
Pflug A; Schimpl M; Nissink JWM; Overman RC; Rawlins PB; Truman C; Underwood E; Warwicker J; Winter-Holt J; McCoull W
Biochem J; 2020 Nov; 477(22):4443-4452. PubMed ID: 33119085
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.
Suárez RM; Chevot F; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
Eur J Med Chem; 2013 Mar; 61():2-25. PubMed ID: 22749189
[TBL] [Abstract][Full Text] [Related]
10. Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development.
Park TH; Bae SH; Bong SM; Ryu SE; Jang H; Lee BI
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114206
[TBL] [Abstract][Full Text] [Related]
11. Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors.
Messoussi A; Peyronnet L; Feneyrolles C; Chevé G; Bougrin K; Yasri A
Molecules; 2014 Oct; 19(10):16223-39. PubMed ID: 25310149
[TBL] [Abstract][Full Text] [Related]
12. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.
Baladi T; Abet V; Piguel S
Eur J Med Chem; 2015 Nov; 105():220-37. PubMed ID: 26498569
[TBL] [Abstract][Full Text] [Related]
13. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.
Huelse JM; Fridlyand DM; Earp S; DeRyckere D; Graham DK
Pharmacol Ther; 2020 Sep; 213():107577. PubMed ID: 32417270
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.
Oza V; Ashwell S; Brassil P; Breed J; Deng C; Ezhuthachan J; Haye H; Horn C; Janetka J; Lyne P; Newcombe N; Otterbien L; Pass M; Read J; Roswell S; Su M; Toader D; Yu D; Yu Y; Valentine A; Webborn P; White A; Zabludoff S; Zheng X
Bioorg Med Chem Lett; 2010 Sep; 20(17):5133-8. PubMed ID: 20673630
[TBL] [Abstract][Full Text] [Related]
15. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Wu F; Büttner FH; Chen R; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Paw Z; Prokopowicz A; Shih CK; Snow R; Young E; Cywin CL
Bioorg Med Chem Lett; 2010 Jun; 20(11):3235-9. PubMed ID: 20462760
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based approaches to the discovery of kinase inhibitors.
Mortenson PN; Berdini V; O'Reilly M
Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
[TBL] [Abstract][Full Text] [Related]
17. New aminopyrimidine derivatives as inhibitors of the TAM family.
Traoré T; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
Eur J Med Chem; 2013; 70():789-801. PubMed ID: 24239626
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
[TBL] [Abstract][Full Text] [Related]
19. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
[TBL] [Abstract][Full Text] [Related]
20. Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors.
Reinecke M; Brear P; Vornholz L; Berger BT; Seefried F; Wilhelm S; Samaras P; Gyenis L; Litchfield DW; Médard G; Müller S; Ruland J; Hyvönen M; Wilhelm M; Kuster B
Nat Chem Biol; 2024 May; 20(5):577-585. PubMed ID: 37904048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
